SXI Life Sciences
7.288,53
PKT
+69,99
PKT
+0,97
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
17.10.12 | Novartis reduce | Vontobel Research | |
17.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
16.10.12 | Novartis neutral | Citigroup Corp. | |
16.10.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
16.10.12 | Novartis outperform | Credit Suisse Group | |
12.10.12 | Novartis outperform | Credit Suisse Group | |
12.10.12 | Novartis buy | Nomura | |
12.10.12 | Novartis reduce | Vontobel Research | |
12.10.12 | Novartis buy | UBS AG | |
11.10.12 | Novartis buy | Deutsche Bank AG | |
11.10.12 | Novartis buy | UBS AG | |
10.10.12 | Sonova underperform | Exane-BNP Paribas SA | |
08.10.12 | Novartis halten | Independent Research GmbH | |
08.10.12 | Novartis reduce | Vontobel Research | |
05.10.12 | Lonza hold | Vontobel Research | |
05.10.12 | Sonova neutral | Sarasin Research | |
05.10.12 | Straumann hold | Vontobel Research | |
05.10.12 | Sonova buy | Vontobel Research | |
04.10.12 | Novartis buy | Nomura | |
02.10.12 | Tecan (N) neutral | Sarasin Research | |
01.10.12 | Novartis buy | Sarasin Research | |
01.10.12 | Novartis reduce | Vontobel Research | |
27.09.12 | Sonova neutral | Sarasin Research | |
27.09.12 | Sonova underperform | Exane-BNP Paribas SA | |
24.09.12 | Novartis reduce | Vontobel Research | |
24.09.12 | Novartis buy | Sarasin Research | |
14.09.12 | Lonza neutral | J.P. Morgan Cazenove | |
13.09.12 | Novartis reduce | Vontobel Research | |
12.09.12 | Novartis neutral | J.P. Morgan Cazenove | |
11.09.12 | Newron PharmaceuticalsAz. buy | Vontobel Research | |
11.09.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
11.09.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
10.09.12 | Newron PharmaceuticalsAz. buy | Vontobel Research | |
07.09.12 | Novartis neutral | J.P. Morgan Cazenove | |
06.09.12 | Novartis neutral | Exane-BNP Paribas SA | |
05.09.12 | Novartis reduce | Vontobel Research | |
04.09.12 | Novartis neutral | J.P. Morgan Cazenove | |
03.09.12 | Novartis reduce | Vontobel Research | |
03.09.12 | Novartis kaufen | Die Actien-Börse | |
31.08.12 | Novartis buy | Deutsche Bank AG |